143759-64-2

Basic information

• Product Name: 1-(benzylamino)-3-{4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl}propan-2-ol
• Synonyms: 1-piperazineethanol, 4-[4,4-bis(4-fluorophenyl)butyl]-alpha-[[(phenylmethyl)amino]methyl]-
• CAS NO: 143759-64-2
• Molecular Formula: C₃₀H₃₇F₂N₃O
• Molecular Weight: 493.6311
• Mol File: 143759-64-2.mol

Chemical Properties

• Boiling Point: 618.8°C at 760 mmHg
• Flash Point: 328°C
• Density: 1.147g/cm³
• Vapor Pressure: 3.59E-16mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: 1-(benzylamino)-3-{4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl}propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(benzylamino)-3-{4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl}propan-2-ol(143759-64-2)
• EPA Substance Registry System: 1-(benzylamino)-3-{4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl}propan-2-ol(143759-64-2)

Safety Data

• Hazardous Substances Data: 143759-64-2(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 143759-57-3 1-[4,4-bis(4-fluorophenyl)butyl]-4-(2,3-epoxypropyl)piperazine 
• 75605-52-6 N-benzyl-3-amino-1-chloropropan-2-ol 
• 5631-35-6 1-[4,4-bis(4-fluorophenyl)butyl]piperazine 

Relevant articles and documents

Novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter

The novel diphenyl piperazine derivatives containing the phenyl substituted aminopropanol moiety, including 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-hydroxy-3-(phenylamino)propyl]piperazine 1, which were modified at the connective between the diphenyl and piperazine moieties, have been found to be potent dopamine uptake inhibitors. To study the further structure-activity relationship (SAR) of these compounds, a new series was synthesized, with modifications at the 2-hydroxy-3-phenylaminopropyl moiety of 1. The series was evaluated for dopamine transporter (DAT) binding affinity with [3H]GBR12935 in rat striatal membranes. Most of the compounds showed moderate to high DAT binding affinities and some were approximately equivalent in activity to compound 1 or GBR12909 as a dopamine uptake inhibitor, with IC50 values of nanomolar range. The SAR suggested that on exhibiting a potent interaction with the DAT, there is probably a steric limitation around the benzene ring of the phenylamino moiety of 1, allowing only small-sized substituents with the exception of basic moieties at the 4-position. In addition, the SAR at the 3-amino-2-propanol moiety of 1 suggested that either the nitrogen atom with an electron donating substituent or the unsubstituted nitrogen atom and also the hydroxy group are desirable for elicitation of a potent DAT binding affinity.

Novel diphenylalkyl piperazine derivatives with dual calcium antagonistic and antioxidative activities

Two types of novel diphenylalkyl piperazine derivatives containing the thio or aminopropanol moiety substituted by phenyl or benzyl group were synthesized, and evaluated for their calcium antagonistic and antioxidative activities. These compounds showed apparent inhibitions against KCl-induced contractions in isolated rat aorta. Among them, phenylamino compound 9 and benzylamino compound 13 also possessed potent inhibitory activities against auto-oxidative lipid peroxidations in canine brain homogenates. Two representative compounds 3a and 9 were evaluated for their inhibitory activities against KCl-induced contractions in isolated canine arteries (basilar, coronary, mesenteric, and renal). Both compounds showed the most potent inhibitions to basilar artery.

Diphenylpiperazine derivative and drug for circulatory organ containing the same

A diphenylpiperazine derivative represented by general formula (1), salt thereof, and drug for the circulatory organs containing the same as the active ingredient: STR1 wherein R1 and R2 may be the same or different from each other a